Recall Classification and Timelines for Medical Devices in Tanzania
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Tanzania classifies recalls into three classes by risk and sets maximum recall timelines. Regulation 66 of GN 315 provides:
Regulation 66(1) — the three class definitions:
- Class I: defective, dangerous or likely life-endangering devices, where the defect predictably or probably will cause serious health risks, adverse events or death;
- Class II: devices that may possibly cause temporary or medically reversible adverse health problems, or mistreatment;
- Class III: devices that are defective but unlikely to cause any adverse health reaction, or devices that do not comply with the requirements of the Act.
Regulation 66(2) — maximum recall timelines: Class I 14 days, Class II 21 days, Class III 30 days.
Regulation 66(3): notwithstanding these limits, TMDA retains the power to determine the maximum time for a recall according to the urgency and health risk involved.
2. Legal basis
| Instrument | Reference / Number | Publication date | Provisions |
|---|---|---|---|
| The Tanzania Food, Drugs and Cosmetics (Control of Medical Devices) Regulations, 2015 | GN. No. 315 | 31 July 2015 | Regulations 63, 64, 65, 66(1), 66(2) and 66(3); Regulations 39 and 40 (distribution records); Regulation 9(c) (LRP handles recalls) |
| Guidelines on Submission of Application for Change(s) to Approved Medical Devices and In-Vitro Diagnostics | TMDA/DMD/MDA/G/003 | June 2022 | §6.2 (Changes Triggered by Recall) |
3. Expert insights
Insight one: the wording of the three classes forms an operational probability grading.
Class I uses predictably or probably; Class II uses possibly; Class III uses unlikely. These are not vague phrases but probability thresholds. In a self-assessment, companies should map their case onto these three words rather than grade by instinct. Undergrading relaxes the timeline under Regulation 66(2) — which in practice means the company itself is carrying the risk of an insufficiently urgent recall.
Insight two: Regulation 66(3) is an override clause in favour of TMDA, and companies cannot invoke it in reverse.
Regulation 66(3) allows TMDA to set a different maximum recall time according to the urgency and health risk involved. The practical meaning is that classifying a recall as Class III (30 days) does not mean TMDA accepts 30 days; the authority may require a shorter period at any time. Recall drills should therefore be built around the strictest class.
Insight three: recall capability and distribution records are paired — Regulation 39(2) sets the design standard for the records.
Regulation 39(2): distribution, sale and user records must contain traceability information sufficient to support the complete and rapid withdrawal of devices from the market. Regulation 40: records are kept for the expected lifetime of the device and for 2 years after shipment, and must permit timely retrieval. Without this records infrastructure, a 14-day Class I recall is technically impossible to execute.
Insight four: handling recalls is one of the four statutory duties of the LRP.
Regulation 9(c) states expressly that the LRP shall Handle medical device recalls. Combined with the reporting duty holders of Regulation 41 (registrants, manufacturers, importers, distributors), this creates a dual channel of reporting plus execution. An overseas manufacturer must ensure that its LRP has genuine recall execution capability, not merely a forwarding function for notices.
Insight five: design changes triggered by a recall follow a special route.
TMDA/DMD/MDA/G/003 §6.2: changes arising from a recall must be assessed for whether they are significant, including design changes or design specification changes needed to restore the device to its original performance specifications; the cover letter of an application responding to a recall must clearly state that it is submitted for that purpose; the applicant should contact TMDA directly before submitting; and the review time for such post-recall change applications will be determined taking into account the nature of the change and any potential safety considerations.
4. Practical recommendations
- Build a classification self-check table around the three probability words of Regulation 66(1) and document the rationale for each classification decision.
- Run recall drills at the Class I (14-day) standard, even if the product has only ever presented Class III scenarios.
- Design distribution record fields to the complete-and-rapid-withdrawal standard and test retrieval periodically (Regulation 39(2)).
- Spell out recall execution authority and capability requirements in the LRP agreement (Regulation 9(c)) and run one tabletop exercise.
- Route post-recall design changes through the §6.2 special channel: state in the cover letter that the application responds to a recall, and contact TMDA before submitting.
- Run recall and vigilance reporting in parallel: the recall itself is a Regulation 66 matter, but if the triggering event meets the conditions of Regulation 41, it must still be reported within 24 hours or 14 days.
5. Verification checklist
- □ A classification self-check table has been built around the three probability words of Regulation 66(1) (predictably or probably, possibly, unlikely).
- □ The maximum recall timelines are understood: Class I 14 days, Class II 21 days, Class III 30 days (Regulation 66(2)).
- □ It is understood that TMDA may set a different timeline under Regulation 66(3).
- □ Distribution records are designed to the complete-and-rapid-withdrawal standard of Regulation 39(2) and retrieval is tested periodically.
- □ The LRP agreement states recall execution authority and capability (Regulation 9(c)), and a tabletop exercise has been completed.
- □ Post-recall design changes follow the §6.2 special route.
- □ The recall track and the vigilance reporting track run in parallel.
Regulatory information verified as of 29 October 2026. All provisions cited in this document were checked against the official TMDA published texts (GN. No. 315, Regulations 9(c), 39–41 and 63–66; TMDA/DMD/MDA/G/003 §6.2) and will be re-reviewed when the regulations are updated.
- Local resources in Tanzania: GRZAN can coordinate a licensed Local Responsible Person (LRP) and distributor resources, covering online submission, sample delivery, quality audit support, and port clearance.
- Service capabilities: classification determination, route selection between registration and notification, technical documentation (CSDT/STED) preparation and localization, GMDN coding and grouping strategy, clinical evidence organization, software and AI-enabled device submissions, change management, vigilance and PMS reporting, and annual retention fee and renewal management.
- Contact GRZAN for registration documentation and conformity support for the Tanzania market: info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us